Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer—A Likely Limited Role on a Deep Bench

Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer—A Likely Limited... Editorial Opinion Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer—A Likely Limited Role on a Deep Bench Ibiayi Dagogo-Jack, MD Since the groundbreaking approval of crizotinib for the treat- proved for first-line treatment. Indeed, across phase 3 studies ment of advanced ALK-rearranged (ALK-positive) non–small comparing alectinib (ALEX), brigatinib (ALTA-1L), and now en- cell lung cancer (NSCLC) in 2011, the therapeutic landscape sartinib (eXalt3) with crizotinib, the median progression-free for this disease has evolved at a staggering pace. Indeed, the survival by blinded review is consistently 24 to 25 months, with past decade has witnessed an approximately 50% reduction in the risk of progression or 2,4 US Food and Drug Adminis- death compared with crizotinib. Although intracranial re- Related article page 1617 tration approvals of 4 addi- sponses to the various drugs cannot be directly compared and tional ALK tyrosine kinase inhibitors (TKIs): ceritinib, alec- the number of patients with measurable brain metastases was 2-5 tinib, brigatinib, and lorlatinib. These next-generation ALK limited in the studies, it is reassuring overall that these 3 second- TKIs represent a significant advance compared with the first- generation ALK TKIs boast impressive intracranial activity in generation ALK TKI crizotinib in terms of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer—A Likely Limited Role on a Deep Bench

JAMA Oncology , Volume 7 (11) – Nov 2, 2021

Loading next page...
 
/lp/american-medical-association/inserting-ensartinib-into-the-starting-lineup-for-alk-rearranged-lung-IQOW0tm7J4
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2021.3369
Publisher site
See Article on Publisher Site

Abstract

Editorial Opinion Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer—A Likely Limited Role on a Deep Bench Ibiayi Dagogo-Jack, MD Since the groundbreaking approval of crizotinib for the treat- proved for first-line treatment. Indeed, across phase 3 studies ment of advanced ALK-rearranged (ALK-positive) non–small comparing alectinib (ALEX), brigatinib (ALTA-1L), and now en- cell lung cancer (NSCLC) in 2011, the therapeutic landscape sartinib (eXalt3) with crizotinib, the median progression-free for this disease has evolved at a staggering pace. Indeed, the survival by blinded review is consistently 24 to 25 months, with past decade has witnessed an approximately 50% reduction in the risk of progression or 2,4 US Food and Drug Adminis- death compared with crizotinib. Although intracranial re- Related article page 1617 tration approvals of 4 addi- sponses to the various drugs cannot be directly compared and tional ALK tyrosine kinase inhibitors (TKIs): ceritinib, alec- the number of patients with measurable brain metastases was 2-5 tinib, brigatinib, and lorlatinib. These next-generation ALK limited in the studies, it is reassuring overall that these 3 second- TKIs represent a significant advance compared with the first- generation ALK TKIs boast impressive intracranial activity in generation ALK TKI crizotinib in terms of

Journal

JAMA OncologyAmerican Medical Association

Published: Nov 2, 2021

References